Ev3: Sales of neurovascular products grew 37% to $45.2 million in the third quarter, including $28.4 million in revenues from embolic devices, the Plymouth, Mass., company said Oct. 27. The growth was driven by Axium aneurysm occlusion coils and Onyx liquid embolic neurovascular access devices and balloons, as well as overseas sales of the Pipeline embolization device. Ev3 gained Pipeline through its acquisition of Chestnut Medical in June and expects U.S. approval of the device in 2011 (1"The Gray Sheet" June 8, 2009). Peripheral vascular sales rose 1% to $67.6 million, reflecting continued weakness in its atherectomy business. The company is hoping its recently bulked up atherectomy sales force and new TurboHawk atherectomy system will have an impact on ev3. The firm announced it was adding 27 reps to market the SilverHawk plaque excision system in April. Total sales for the quarter were $112.8 million, up 13% (not including $7 million in extra 2008 funds from a now-terminated agreement with Merck). Ev3 projects fiscal 2009 sales between $446 million and $450 million
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.
Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.
In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul
Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.
Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.
Speakers at a recent UK medtech outlook conference voiced optimism about the sector’s prospects, but warned that cost burdens, over-regulation and lengthy processes will impede the capacity of local SMEs to innovate. Only 10% of NHS procured medtech comes from UK manufacturers.